Taylor & Francis Group
Browse
idrd_a_1998248_sm7296.docx (90.73 kB)

Enhanced oral bioavailability of koumine by complexation with hydroxypropyl-β-cyclodextrin: preparation, optimization, ex vivo and in vivo characterization

Download (90.73 kB)
journal contribution
posted on 2021-11-12, 09:00 authored by Qing Hu, Xiaoling Fu, Yanping Su, Yanfang Wang, Sihuan Gao, Xiaoqin Wang, Ying Xu, Changxi Yu

Koumine (KME) is an active alkaloid extracted from Gelsemium elegans, and its diverse bioactivities have been studied for decades. However, KME exhibits poor solubility and low oral bioavailability, which hampers its potential therapeutic exploitation. This work aimed to develop optimized inclusion complexes to improve the bioavailability of KME. The KME/hydroxypropyl-β-cyclodextrin (KME/HP-β-CD) inclusion complexes were prepared by the solvent evaporation method and later optimized using the Box-Behnken design. The optimal KME/HP-β-CD was characterized by scanning electron microscopy, Fourier transforms infrared spectroscopy, differential scanning calorimetry, and nuclear magnetic resonance spectroscopy. The physicochemical characterization results revealed that the crystalline state of KME was transformed into an amorphous form, forming KME/HP-β-CD inclusion complexes. Compared with KME, the solubility and in vitro release rate of KME/HP-β-CD was significantly enhanced by 52.34- and 1.3-fold, respectively. Further research was performed to investigate the intestinal absorption characteristics and in vivo bioavailability in rats. The optimal KME/HP-β-CD showed enhanced absorptive permeability and relative bioavailability increased more than two-fold compared to that of raw KME. These results indicate that the optimal KME/HP-β-CD can be used as an effective drug carrier to improve the solubility, intestinal absorption, and bioavailability of KME.

Funding

This work was supported by the National Natural Science Foundation of China (81973309, 82003663); the Science and Technology Agency of Fujian Province, China (2019J01302); Joint Funds for the Innovation of Science and Technology, Fujian province (2018Y9074, 2019Y9006); Startup Fund for scientific research, Fujian Medical University (2018QH1011).

History